TNF and arthritic joint disease: Similarly, it has been demonstrated that the S1P receptor modulator fingolimod (FTY720), when administered orally to DBA/1J mice at 2 mg/kg daily for 35 days, markedly suppressed CD4+ T-lymphocyte recruitment to the joints in a collagen-induced arthritis model, while in MH7A cell cultures, it inhibited TNF-α-induced activation of PI3K/Akt/NF-κB and reduced secretion of IL-1β, IL-6, and IL-8 [20].